Taken together, our study might guide as basis for further translational research and suggest that dual blockade of PD-1 and CTLA-4 might enhance the therapeutic activity when compared to monotherapy in breast cancer, thereby unraveling potential benefit for patients. Here, PDCD1 is linked to breast carcinoma.